DIACEUTICS PLC

Regulatory Filings • Aug 5, 2025

National Storage Mechanism | Additional information

RNS Number : 9165T

Diaceutics PLC

05 August 2025

Reach

Diaceutics Presenting at Canaccord Genuity 45th Annual Growth Conference

New York, Belfast and London, 05 August 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry today announces that management will attend and present at the Canaccord Genuity 45th Annual Growth Conference taking place on August 12-13, 2025 in Boston, MA.

The Conference brings together investors from around the world with some of the best and most promising growth companies in Canaccord's core sectors - Technology, Healthcare, Digital & Tech-Enabled Health, Sustainability, Industrials, and Consumer & Retail.

Enquiries:  

Diaceutics PLC
Ryan Keeling, Chief Executive Officer   Nick Roberts, Chief Financial Officer	Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com
Canaccord Genuity Limited (Nomad & Broker)	Tel: +44 (0)20 7523 8000
Simon Bridges, Andrew Potts, Harry Rees

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

About Reach Announcements

Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASSFFMLEISEDA